Global Automated Immunoassay Analyzers Market 2025–2034

Reports Description

Global Automated Immunoassay Analyzers Market size was valued at USD 24.34 Billion in 2025 and is anticipated to reach around USD 75.31 Billion by 2034, expanding at a CAGR of 15.35% over the forecast period 2025 - 2034.

Automated Immunoassay Analyzers Market Overview

A growing trend toward lab automation and a higher incidence of infectious diseases accompanies the growth. These products are experiencing an increase in prominence due to the expanded clinical applications and incremental innovation to the existing products.

The global automated immunoassay analyzer market is being driven by the introduction of innovative products, which is a result of the current trends of automation and integration. Various pharmaceutical and biotechnology companies are progressively employing them for the purpose of drug discovery.

During the research period, the North American Automated Immunoassay Analyzers market is anticipated to continue to dominate the overall sector. A strategic presence of key manufacturers drives the market. The market is primarily driven by the increasing demand for clinically efficient immunoassay analyzers and the high adoption of technology in the United States during the forecast period.

The regional revenue share in 2023 was more than 85% influenced by the U.S. automated immunoassay analyzer market. Business expansion is anticipated to be facilitated by the rapid adoption of automated technology in diagnostic laboratories and favorable government policies.

Immunoassays are bioanalytical methods that quantify the molecular concentration of a solution by employing an antibody and antigen. The quantity of the analyte in the solution is contingent upon the reaction between the antigen and antibody. Immunoassay is a widely used method for identifying the presence of a specific substance in the human body, such as a pathogen, hormone, antigen, antibody, or enzyme.

Immunoassays are employed in a variety of disciplines, such as clinical chemistry. They are employed due to their specificity, sensitivity, criticality, and rapidity. Additionally, immunoassays are employed in the pharmaceutical and biotechnology and food and beverage industries for pharmaceutical analysis, including disease diagnosis, therapeutic drug monitoring, drug efficacy, bioequivalence studies, clinical pharmacokinetics, and pharmacodynamics.

Their applications extend beyond diagnostics. The significance of immunoassay techniques is derived from their inherent specificity, rapid detection, and high-throughput capabilities, which enable the analysis of a diverse array of substances in biological samples.

Automated Immunoassay Analyzers Market Growth Factors

• The market's revenue is anticipated to increase during the forecast period due to the increasing prevalence of a variety of chronic diseases, which in turn leads to the adoption of advanced diagnostic solutions.

• The global automated immunoassay analyzers market is anticipated to experience revenue growth during the forecast period due to the rapid adoption of these devices and the subsequent increase in demand from the increasing use of automated immunoassay analyzers.

• It is anticipated that the market will experience a significant increase in growth in the years ahead due to the significant transition to automated laboratories.

• The automated immunoassay analyzers market is expected to experience growth during the forecast period due to the increasing healthcare expenditures and the geriatric population.

• The market is expected to experience substantial growth opportunities due to the increasing emphasis on diagnostic accuracy and technological advancements.

• The increased number of new product launches is anticipated to enhance the company's global market position and broaden its geographic reach.

Automated Immunoassay Analyzers Market Trends

One of the primary factors contributing to the growth of the automated immunoassay analyzers market is the increasing prevalence of chronic and infectious diseases, including HIV, cardiovascular disease, cancer, diabetes, and autoimmune disorders.

Immunoassays are essential for the early detection of diseases and the prevention of complications through early treatment. Various analytes in biological samples, including urine and blood, are detected and quantified using immunoassay techniques by the automated immunoassay analyzer.

The determination of infectious diseases is facilitated by the growing utilization of technologically advanced immunoassay analyzers. The effective planning of treatment will be facilitated by the precise diagnosis of microorganism-based maladies. Consequently, the market has experienced development as a result of the escalating prevalence of chronic diseases all over the world.

• In 2022, the World Health Organization (WHO) reported an estimated 20 million new cancer cases and 9.7 million fatalities. Approximately one in five individuals will develop cancer during their lifetime, and approximately one in nine males and one in twelve women will succumb to the disease.

• The Institute for Health Metrics and Evaluation's June 2023 report indicates that globally, over half a billion individuals are currently afflicted with diabetes. This condition affects individuals of all ages, including men, women, and children. It is anticipated that the number of diabetes cases will increase from 529 million to 1.3 billion over the next three decades.

Diabetes is one of the most prevalent causes of mortality and disability, with a current global prevalence rate of 6.1%, according to the most recent estimates. The highest rate is 9.3% in North Africa and the Middle East at the regional level, and it is expected to rise to 16.8% by 2050. The rate in Latin America and the Caribbean is expected to rise 11.3%.

Automated Immunoassay Analyzers Market Opportunity

Technological advancements

The industry has been presented with a series of lucrative opportunities due to the efficient and user-friendly application of numerous technological advancements in the automated immunoassay analyzers market. The most optimistic advancements in the field are the simultaneous detection of immunoassays with advanced solutions and the integration of AI into the systems.

Laser-based detection systems provide enhanced sensitivity, specificity, and dynamic range compared to conventional detection methods. These analyzers can accurately measure low-abundance analytes in complex biological samples by utilizing lasers to excite fluorescent labels or chemiluminescent substrates, thereby achieving enhanced signal detection and quantification of biomolecules.

Automated Immunoassay Analyzers Market Restrictions

Inadequate professional expertise: The automated immunoassay analyzers market is expected to be impeded by the scarcity of competent professionals in the healthcare sector. A specific set of talents is necessary to operate automated immunoassay analyzers.

Furthermore, the market's expansion is constrained by the absence of sophisticated healthcare infrastructure and a lack of awareness regarding advanced diagnostic instruments in economically backward regions or underdeveloped countries.

Automated Immunoassay Analyzers Market Segmentation Analysis

By Product

In 2024, the chemiluminescence segment held the majority of the automated immunoassay analyzers market due to its high sensitivity and accuracy in diagnosing low concentrations of analytes. Chemiluminescence immunoassay is a laboratory technique that is frequently employed to identify particular analytes.

It aids in identifying and analysing various substances, including antibodies, antigens, enzymes, fatty acids, hormones, and proteins. It is also employed in the disciplines of environmental monitoring, drug analysis, life science, and clinical diagnosis.

It is anticipated that the Immunofluorescence segment will experience a substantial increase in market share during the forecast period. Healthcare personnel utilize this automated immunofluorescence analyzer to diagnose a variety of health conditions, including cancer, diabetic complications, cardiovascular disease, renal injury, and pregnancy. This instrument yields quantitative and dependable results for diverse analytes in human urine and blood.

By Application

The automated immunoassay analyzers market was dominated by the infectious diseases segment in 2023, and this trend is anticipated to continue throughout the forecast period. The healthcare sector increasingly utilises automated immunoassay analyzers due to the growing prevalence of infectious diseases worldwide, including coronavirus (COVID-19), hepatitis, influenza, HIV, measles, and others.

The chronic diseases segment is anticipated to experience substantial growth during the forecast period. The segment is experiencing growth due to the increasing prevalence of chronic diseases, such as cancer, heart disease, stroke, type 2 diabetes, and arthritis, on a global scale.

The demand for sophisticated diagnostic solutions for accurate disease diagnosis and monitoring is on the rise due to the increasing prevalence of chronic diseases. These automated immunoassay analyzers are essential instruments in clinical diagnostics due to their high throughput, accuracy, and efficiency. Consequently, this contributes to the expansion of the segment.

By End User

In 2024, the automated immunoassay analyzers market was primarily dominated by the hospitals segment. The primary factor driving the segment's growth is the increasing utilization of automated immunoassay analyzers by healthcare professionals and physicians in hospitals to detect and monitor diseases in patients. Furthermore, the availability of skilled professionals, the presence of a well-established healthcare infrastructure, and the access to advanced instruments to conduct rapid and accurate diagnostic testing.

Report Scope

Automated Immunoassay Analyzers Market Regional Analysis

The highest revenue share of the total market was attributed to North America, which has seen a significant increase in the adoption of advanced healthcare technology products and automated immunoassay analyzers.

This is a significant factor contributing to the anticipated expansion of this region's Automated Immunoassay Analyzers market. Additionally, many patients in this field are moving toward adopting Automated Immunoassay Analyzer test results, enabling them to diagnose more quickly.

A rise in the number of automated immunoassay analytical facilities that are well-established is expected to result in a quicker rate of growth in the Asia Pacific region during the forecast period. Major research institutes and research and development (R&D) facilities are located in the region, which is contributing to the acceleration of market growth.

A significant number of ongoing research studies and the global expansion of the healthcare sector are among the factors that are anticipated to contribute to the expansion of this market.

To learn more about this report - request a sample report PDF

Automated Immunoassay Analyzers Market Recent Advancements

• EUROIMMUN introduced the UNIQO 160 automated indirect immunofluorescence test (IIFT) system in June 2023 to diagnose autoimmune diseases. The new test enhances the efficacy of each stage of the IIFT procedure, including image analysis and capture, slide washing and mounting, sample preparation, incubation, and mounting. The new all-in-one solution is now available in countries that recognize the CE mark, as the company has obtained the certificate of compliance with the European In Vitro Diagnostic Medical Device Regulation.

• In March 2023, bioMérieux, a prominent global participant in in vitro diagnostics, made a strategic investment in Proxim Diagnostics. The funds will be allocated to the completion of the development and launch of Proxim's Profile System, a mobile immunodiagnostic tool that is completely automated and utilizes disposable cartridges to conduct various multiplexed tests.

• In February 2023, Epitope Diagnostics, Inc. announced the availability of panel kits that include both common and specialized chemiluminescence immunoassay tests across various clinical domains. These kits are in addition to the company's fully automated chemiluminescence immunoassay analyzers (ECL25 and ECL100).

List of the prominent players in the Automated Immunoassay Analyzers Market:

• Abbott Laboratories
• Arlington Scientific Inc.
• Becton Dickinson and CompanyB
• Bio-Rad Laboratories Inc.
• Biobase Biodusty(Shandong), Co. Ltd.
• bioMerieux SA
• Carolina Liquid Chemistries Corp.
• Charles River Laboratories
• Chengdu Vacure Biotechnology Co. Ltd.
• Danaher Corporation
• Hoffmann-La Roche AG
• Getein Biotech Inc.
• Hipro Biotechnology Co. Ltd.
• Illumina Inc.
• Laboratory Corporation of America Holdings
• Medline Industries LP
• Meril Life Sciences Pvt. Ltd.
• PerkinElmer Inc.
• Qiagen N.V.
• Randox Laboratories
• Siemens Healthineers
• Sysmex Corporation
• Arlington Scientific
• Becton Dickinson and Company
• Carolina Liquid Chemistries Corporation
• Roche Diagnostics
• BioMerieux
• Aesku Diagnostics
• Others

The Automated Immunoassay Analyzers Market is segmented as follows:

By Product

• Immunofluorescence
• Chemiluminescence
• Enzyme Linked Fluorescent System
• Radioimmunoassay

By Application

• Infectious Diseases
• Endocrinology
• Drug Monitoring
• Chronic Diseases
• Allergy Testing

By End User

• Academic Research Institutes
• Biotech And Pharma Companies
• Hospitals
• Diagnostic Test Laboratories
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America